Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the transaction, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Aura Biosciences Stock Performance
Shares of AURA stock opened at $5.40 on Thursday. The stock's 50-day moving average is $6.80 and its two-hundred day moving average is $8.21. Aura Biosciences, Inc. has a 1 year low of $4.74 and a 1 year high of $12.38. The firm has a market cap of $271.22 million, a price-to-earnings ratio of -3.12 and a beta of 0.43.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). As a group, research analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.
Hedge Funds Weigh In On Aura Biosciences
Hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock worth $1,233,000 after purchasing an additional 3,612 shares during the last quarter. State Street Corp grew its holdings in shares of Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company's stock worth $6,725,000 after buying an additional 26,841 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Aura Biosciences during the 3rd quarter worth approximately $1,037,000. Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after purchasing an additional 43,897 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after purchasing an additional 39,379 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on AURA. JMP Securities set a $19.00 price objective on shares of Aura Biosciences in a report on Wednesday, March 26th. Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Finally, HC Wainwright set a $25.00 target price on Aura Biosciences in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $22.75.
Check Out Our Latest Analysis on Aura Biosciences
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
